

ASX ANNOUNCEMENT

Appendix 4C – Quarterly Cash Flow Report

Highlights for the quarter ended 31st December 2016

- \$1,155k R & D Tax Incentive refund received
- Share placement announcement in January to Dr M. Monsour \$383k (subject to shareholder approval)
- Share placement announcement in January to INOV8 of \$277k (subject to shareholder approval of Dr Monsour)
- Share placement announcement in January to Mr R. Mangelsdorf of \$60k (subject to shareholder approval)
- Share placement announcement in January of \$722k to non-related parties
- Cash balance as of 31st December, \$1,228k

31st January 2017: Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® System, has today released its Appendix 4C - Quarterly Cashflow report for period ending 31 December 2016.

During the quarter, the company received \$1,155k of R&D tax credit.

The total cash outflow was \$886k in line with projection. Receipts from sales of PeriCoach in Analytica's key markets of Australia, the UK and the US totalled \$15k, with extremely limited commercial activity occurring. PeriCoach placements generated are for the benefit of furthering R & D and to solidify a licencing deal.

The Board and management appreciate the confidence of our major shareholders for supporting share placements (without discount), totalling \$1,442k, which ensures the company has sufficient capital to complete the roll out of V3 and advance negotiations with a licencing partner.

PeriCoach is a regulated medical device, built as a data collection system. The system provides opportunity for elevated insights into management and motivation of the conservative treatment pathway for female pelvic floor disorders. This core capability is the driver for the pursuit of clinical evidence, in the forms of studies and surveys, as well as development of enhanced functionality of the PeriCoach system. Continued investment in real world data gathering tools to increase the sophistication of analysis of user behaviour and pelvic health information is the cornerstone of company strategy.

In the previous quarter the FDA provided confirmation that the PeriCoach can be marketed for improved sexual function under "general" wellness claims. With the clinical evidence in progress, as well as consumer feedback, this opportunity is being addressed.

Operationally the company remains tightly focused on release of the PeriCoach System V3. The enhanced functionality in V3 for users will simplify progress improvement reporting, incorporate symptom trackers, provide intuitive training guidance, and elevate the "in-app" experience. Furthermore, the introduction of training programs to address motivation and success factors will be deployed in early 2017. The capabilities of the V3, expands the market opportunity for PeriCoach and adds to the appeal for a potential licensing partner.



Analytica CEO Geoff Daly said: "We are very pleased with the strong vote of confidence in the company by our major and long term shareholders. Analytica is on pace to introduce V3 for real-world market evaluation. The company is focusing on the business activities which will best support the evidence of value and securing of a licence partner for PeriCoach."

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia and New Zealand, UK and Ireland, and in the USA.



Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Analytica Ltd

ABN

12 006 464 866

Quarter ended ("current quarter")

December 2016

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	15	35
1.2 Payments for		
(a) research and development	(283)	(521)
(b) product manufacturing and operating costs	(29)	(56)
(c) advertising and marketing	(93)	(220)
(d) leased assets		
(e) staff costs	(334)	(657)
(f) administration and corporate costs	(155)	(265)
1.3 Dividends received (see note 3)		
1.4 Interest received	4	7
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives	1,155	1,155
1.8 Other (provide details if material)		3
1.9 Net cash from / (used in) operating activities	(280)	(519)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(1)	(2)
(b) businesses (see item 10)		
(c) investments		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
(d) intellectual property		
(e) other non-current assets		
2.2 Proceeds from disposal of:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
2.6 Net cash from / (used in) investing activities	(1)	(2)

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares		500
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options		
3.4 Transaction costs related to issues of shares, convertible notes or options	(3)	(5)
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
3.10 Net cash from / (used in) financing activities	(3)	495

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	952	1,254
4.2 Net cash from / (used in) operating activities (item 1.9 above)	280	(519)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(1)	(2)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	(3)	495

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of quarter	1,228	1,228

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,228	952
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,228	952

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Current quarter \$A'000
110
0

--

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

Current quarter \$A'000

--

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	400	400
8.2 Credit standby arrangements		
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

Announced allotment capital raising of \$1,442k.

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	310
9.2 Product manufacturing and operating costs	85
9.3 Advertising and marketing	120
9.4 Leased assets	
9.5 Staff costs	320
9.6 Administration and corporate costs	120
9.7 Other (provide details if material)	
9.8 Total estimated cash outflows	955

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: Date:
(Director)

Print name: R. Mangelsdorf

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.